GRML Greenland Mines Ltd
Greenland Mines Ltd engages in the cell and gene therapy, and natural resources businesses. The company primarily explores palladium, gold, and platinum deposits. It focuses on the exploration and development of Skaergaard project located in Southeast Greenland and the Sarartoq neodymium-praseodymium (Nd-Pr) rare earths project in Southwest Greenland. The company is also involved in the development of KLTO-202, a gene therapy for the treatment and prevention of amyotrophic lateral sclerosis; and KLTO-101 for the treatment or prevention of Alzheimer's disease, as well as therapies to treat Parkinson's and other age-related disorders. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.…
Industry Peers
Other Precious Metals & MiningKey Statistics
About Greenland Mines (NASDAQ: GRML)
›
Greenland Mines (NASDAQ: GRML) is listed on Nasdaq, where its shares trade in USD. It belongs to the Other Precious Metals & Mining industry, part of the Basic Materials sector, and reports about 5 employees.
The shares were at 2.910 USD on 19 November 2026, down 88.0% over 52 weeks. Its 52-week range is 2.820 USD to 37.00 USD: the price is 92.1% below the high and 3.2% above the low.
Its market capitalisation is 43.12M USD.
Greenland Mines reports return on equity of -111.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 9.05M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.